Oric Pharmaceuticals (ORIC) Stock
Clinical stage cancer company targeting treatment resistance. Here's the price, business snapshot, and what's worth knowing about Oric Pharmaceuticals in October 2026.
ORIC Pharmaceuticals is a clinical‑stage oncology company developing targeted therapies intended to overcome mechanisms of treatment resistance in cancer. The business focuses on small molecules and biologics designed to restore or enhance tumour sensitivity to established treatments. As a clinical-stage developer, ORIC’s prospects are closely tied to trial outcomes, regulatory decisions and partner collaborations rather than stable commercial revenues. The company carries typical biotech risks: clinical and regulatory uncertainty, high research and development burn, and potential dilution from future financings. With a market capitalisation around $1.22 billion, the stock can be volatile around data readouts or corporate news. Investors should view ORIC as a higher‑risk, speculative exposure to oncology innovation and consider time horizon, diversification and risk tolerance. This information is educational and general in nature, not personalised investment advice; consider consulting a financial adviser before making investment decisions.
Oric Pharmaceuticals (ORIC) Stock Forecast
Analyst price target, next 12 months
$18.88
+54.6% vs today's $12.21
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Oric Pharmaceuticals have a consensus 12-month target of $18.88, above the current price of $12.21.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ORIC stock, with a target price suggesting it could rise significantly.
Financial Health
ORIC Pharmaceuticals has a solid cash flow and book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can re‑rate the stock, though results are binary and can move the share price materially.
Focused oncology play
ORIC targets mechanisms of treatment resistance, a meaningful clinical need, but commercial success depends on proving benefit versus existing therapies.
Higher‑risk profile
As a clinical‑stage biotech with R&D burn and possible future financing, the stock may be volatile — suitable for investors comfortable with speculative risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
